We are live on ! Find out more
RSCM

Rock Springs Capital Management Portfolio holdings

AUM $1.7B
1-Year Est. Return 93.03%
This Fund
S&P 500
This Quarter Est. Return
+3.29%
1 Year Est. Return
+93.03%
3 Year Est. Return
+228.43%
5 Year Est. Return
+368.14%
10 Year Est. Return
+4,607.77%
AUM
$2.76B
AUM Growth
+$170M
Cap. Flow
+$156M
Cap. Flow %
5.64%
Top 10 Hldgs %
29.4%
Holding
140
New
9
Increased
43
Reduced
9
Closed
5

Top Buys

Rank Stock Value
1
BMY icon
Bristol-Myers Squibb
BMY
+$48.9M
2
ADPT icon
Adaptive Biotechnologies
ADPT
+$26.6M
3
PODD icon
Insulet
PODD
+$25.1M
4
CHRS icon
Coherus Oncology
CHRS
+$21M
5
NBIX icon
Neurocrine Biosciences
NBIX
+$14.7M

Top Sells

Rank Stock Value
1
WMGI
Wright Medical Group Inc
WMGI
+$29M
2
CVET
Covetrus, Inc. Common Stock
CVET
+$17.8M
3
GWPH
GW Pharmaceuticals Plc American Depositary Shares
GWPH
+$16.4M
4
IFRX icon
InflaRx
IFRX
+$8.5M
5
CMTA
Clementia Pharmaceuticals Inc.
CMTA
+$7.18M

Sector Composition

Rank Sector Weight
1 Healthcare 86.18%
2 Consumer Staples 0.39%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
UNH icon
1
UnitedHealth
UNH
$382B
$144M 5.22%
591,000
– –
GWPH
2
DELISTED
GW Pharmaceuticals Plc American Depositary Shares
GWPH
$104M 3.77%
605,000
-95,000
-14% -$16.4M
WCG
3
DELISTED
Wellcare Health Plans, Inc.
WCG
$91.4M 3.31%
320,500
+500
+0.2% +$138K
AMRN
4
Amarin Corp
AMRN
$297M
$87.7M 3.17%
226,250
– –
NBIX icon
5
Neurocrine Biosciences
NBIX
$18.2B
$86.4M 3.12%
1,023,000
+178,500
+21% +$14.7M
ISRG icon
6
Intuitive Surgical
ISRG
$127B
$80M 2.89%
457,500
– –
HCA icon
7
HCA Healthcare
HCA
$90.6B
$61.5M 2.23%
455,000
– –
PCRX icon
8
Pacira BioSciences
PCRX
$1.04B
$54.4M 1.97%
1,250,000
– –
ONCE
9
DELISTED
Spark Therapeutics, Inc. Common Stock
ONCE
$51.7M 1.87%
505,371
-32,129
-6% -$3.47M
EHC icon
10
Encompass Health
EHC
$11.3B
$51M 1.85%
1,011,885
+6,285
+0.6% +$305K
SRPT icon
11
Sarepta Therapeutics
SRPT
$1.64B
$49.4M 1.79%
325,000
-9,500
-3% -$1.15M
BMY icon
12
Bristol-Myers Squibb
BMY
$129B
$47.6M 1.72%
+1,050,000
New +$48.9M
EXAS
13
DELISTED
Exact Sciences
EXAS
$46.9M 1.7%
397,000
– –
TFX icon
14
Teleflex
TFX
$5.96B
$43M 1.56%
130,000
– –
BSX icon
15
Boston Scientific
BSX
$68.4B
$41.7M 1.51%
970,000
– –
CHRS icon
16
Coherus Oncology
CHRS
$217M
$41.5M 1.5%
1,880,000
+1,210,000
+181% +$21M
IRTC icon
17
iRhythm Holdings
IRTC
$4.02B
$39.5M 1.43%
499,615
– –
PEN icon
18
Penumbra
PEN
$12.6B
$38.2M 1.38%
239,000
+14,000
+6% +$2.02M
VRTX icon
19
Vertex Pharmaceuticals
VRTX
$123B
$37.2M 1.35%
203,000
– –
ACHC icon
20
Acadia Healthcare
ACHC
$2.52B
$36.9M 1.33%
1,055,000
+130,000
+14% +$4.2M
RARE icon
21
Ultragenyx Pharmaceutical
RARE
$2.46B
$36.8M 1.33%
580,000
– –
SYK icon
22
Stryker
SYK
$135B
$36.8M 1.33%
179,000
– –
EW icon
23
Edwards Lifesciences
EW
$49.4B
$33.9M 1.23%
550,500
– –
IDXX icon
24
Idexx Laboratories
IDXX
$44.9B
$33.1M 1.2%
120,200
– –
ALXN
25
DELISTED
Alexion Pharmaceuticals
ALXN
$31.8M 1.15%
242,500
– –
1
2 3 4 5

Similar funds

AAM
Alpine Associates Management Palm Beach, Florida $1.7B AUM 97.55% 1-Year Est. Return
SGI
Summit Global Investments Bountiful, Utah $1.69B AUM 12.13% 1-Year Est. Return
ACM
ADAR1 Capital Management Austin, Texas $1.7B AUM 340.85% 1-Year Est. Return
BCM
BlueCrest Capital Management St Helier, Jersey $1.69B AUM 20.01% 1-Year Est. Return
ISS
Intesa Sanpaolo SpA. Turin, Italy $1.69B AUM
PP
PDT Partners New York $1.69B AUM 74.01% 1-Year Est. Return
FDP
Financiere des Professionnels Montreal, Quebec, Canada $1.71B AUM 21.77% 1-Year Est. Return
GAM
Goldentree Asset Management New York $1.69B AUM 10.69% 1-Year Est. Return

Rock Springs Capital Management's Q2 2019 Portfolio in Review

As of Q2 2019, Rock Springs Capital Management held 140 positions worth $2.76B, up 6.6% from $2.59B the previous quarter. Its ten largest holdings account for 29% of the portfolio.

Rock Springs Capital Management deployed $156M of net new capital in Q2 2019, opening 9 new positions and adding to 43 existing holdings. Its largest new stake was Bristol-Myers Squibb: 1,050,000 shares worth $47.6M.

By sector, the portfolio is most concentrated in Healthcare at 86% of assets, up from 85% a quarter earlier, followed by Consumer Staples.

On the sell side, the largest reduction was Covetrus, Inc. Common Stock, an estimated $17.8M trimmed.

  • Rock Springs Capital Management's largest Q2 2019 buy was Bristol-Myers Squibb: 1,050,000 shares worth $47.6M.
  • Rock Springs Capital Management added most to Coherus Oncology in Q2 2019, an estimated $21M increase.
  • Rock Springs Capital Management's biggest Q2 2019 reduction was Covetrus, Inc. Common Stock, cutting an estimated $17.8M.
  • Rock Springs Capital Management fully exited Wright Medical Group Inc in Q2 2019, selling an estimated $29M.
  • Rock Springs Capital Management's ten largest holdings make up 29% of its $2.76B portfolio in Q2 2019.
  • Rock Springs Capital Management opened 9 new positions and closed 5 in Q2 2019.
  • Rock Springs Capital Management's portfolio value rose 6.6% quarter-over-quarter to $2.76B.

Based on Rock Springs Capital Management's 13F filing for Q2 2019, filed 14 Aug 2019.